Background: Statins are cholesterol-lowering drugs that are widely used to reduce the risk of cardiac infarction. Their beneficial clinical effects, however, are not restricted to their influence on cholesterol production. As several studies have shown that they have a potency of relaxing blood vessels.
Background
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) are drugs widely used in the treatment of hypercholesterolaemia. A large number of clinical trials (4S, CARE, WOSCOPS) has demonstrated that treatment of patients with statins reduces the number of cardiac or cerebral ischaemic events even in the absence of further reduction in serum cholesterol levels [15, 16] .
In addition to their lipid-lowering activity, statins seem to possess relevant properties that target multiple mechanisms contributing to the progression of arteriosclerosis: leucocyte adhesion, macrophage stimulation, inflammatory responses, smooth muscle cell activation, and endothelial dysfunction. In patients with moderate hypercholesterolaemia, treatment with simvastatin improved both the acetylcholine-stimulated and basal nitric oxide mediated vasodilatation measured by use of strain-gauge plethysmography within one month [14] . Simvastatin produced relaxation of small resistance arteries of the rat through a mevalonate sensitive pathway [1] . Moreover, it was shown that simvastatin and atorvastatin reduced the concentration of endothelin 1 (ET-1) via a decreased expression of pre-pro ET-1 mRNA in bovine aortic endothelial cells. This effect persisted after the addition of oxidized low-density lipoprotein cholesterol [7] . Various statins inhibited superoxide anion (O 2 -) formation and improved nitric oxide (NO) dependent vasodilatation through an influence on the NO/O 2 -balance in the vessel wall [18] .
In endothelial cells, after treatment with simvastatin and lovastatin an up to 3.8 fold increase of eNOS expression was measured [9] . Other experiments have provided evidence for improved NOS mRNA stability after treatment with simvastatin [10] . Further it was shown that pravastatin and simvastatin increased the endothelium-dependent vasorelaxation in aortic rings and also the NO production by cultured bovine aortic endothelial cells [8] .
Although these properties of statins may be relevant for their beneficial effects on cardiovascular diseases, they do not elucidate the signal pathway of statins on acute endothelium-dependent relaxation of blood vessels. eNOS is a calmodulin-binding enzyme and is abundantly expressed in endothelial cells. An increase of the cytosolic free calcium concentration subsequent to receptor stimulation through agonists like histamine or bradykinin is the main signal for stimulation of synthesis of NO in endothelial cells.
The aim of the present study was therefore to investigate the possible role of free intracellular calcium in the pathway of statin-induced endothelium dependent relaxation. For this purpose we examined the influence of two different statins (cerivastatin and fluvastatin) on agonistinduced transients and resting levels of [Ca 2+ ] i in cultured human endothelial cells.
Methods
Endothelial cells from human umbilical vein (HUVEC-p, Promocell, Heidelberg, Germany) were cultured in EGM-MV Bulletkit medium (BioWhittaker, Verviers, Belgium) containing 0.1% human endothelial growth factor, 0.1% hydrocortison, 5% human serum, 0.4% bovine brain extract, 0.1% gentamycin. Cultures were maintained at 37°C in a fully humidified atmosphere with 5% CO 2 up to passage 6. SH-SY5Y human neuroblastoma cells (DSMZ Braunschweig, Germany) were cultured in DMEM medium containing 10% fetal calf serum (Gibco, Life Technologies, Eggenstein, Germany) in 10% CO 2 . Cells were detached from the culture bottles by exposure to 0.5 g/l trypsin in a Ca 2+ -and Mg 2+ -free solution for approximately 180 s and plated on gelatine-coated glass coverslips.
Changes of [Ca 2+ ] i were measured fluorimetrically. The plated cells were loaded with Fura-2-AM (Molecular Probes, Eugene, USA) by incubating them for 40 min and 37°C at a dye concentration of 1 µM. After incubation, cells were washed 2 times with Krebs solution (see below) to remove extracellular Fura-2-AM. Fluorescence measurements were performed with a combination of a scanning monochromator and a CCD camera operated by TILLvisION software (Till Imago, T.I.L.L Photonics, Gräfelfing, Germany). The camera was mounted to an inverted microscope (Axiovert 100, Carl Zeiss, Jena, Germany) with a 40x objective (Neofluar, Carl Zeiss). Cells were exposed to alternating excitation light pules of 340 and 380 nm wavelength of each 200 ms at intervals of 2 s. Emission images were collected during these pulses. Fluorescence values were corrected for background fluorescence before starting data collection from the emission images. Per experiment up to 8 cells were analyzed simultaneously by defining corresponding areas of interest in the images. The fluorescence intensity ratio (FR), which is related to [Ca 2+ ] i , was calculated for single cells over the whole experiment by forming the ratio of the fluorescence values at 340 and 380 nm excitation: FR = F 340 / F 380 [6] .
During the measurements, cells were continuously superfused with Krebs solution containing (in mM): NaCl 140, KCl 6, CaCl 2 1.5, MgCl 2 1.2, HEPES 11.5, Glucose 10 and adjusted to pH 7.3 with 1 M NaOH; osmolarity was 295 mOsm. The application of all solutions was performed with an application tip located 3 mm away from the measured cells.
Cerivastatin (Bayer AG, Leverkusen, Germany) and fluvastatin (Novartis Pharma AG, Basel, Switzerland) were generously supplied by the respective companies. Cerivastatin and fluvastatin were dissolved in water [13] . N-Omega-Nitro-L-Arginine (L-NAME) and histamine were purchased from Sigma-Aldrich Chemie (Taufkirchen, Germany).
To examine the long-term effects of statins on intracellular calcium homeostasis, cells were treated with the statins one day after seeding by adding appropriate volumes of stock solutions to the cell culture. Cells kept under the same conditions, but without statin treatment, served as control groups.
After 24 h statin incubation the cells were loaded with Fura-2-AM. FR was measured for 20 s under resting conditions, followed by an application of 10 µM histamine for 60 s and washed out for about 120 s. The mean value of FR of each cell measured over 10 s was used for further analysis. To calculate the changes of FR after 24 h incubation of statins, the FR-values of the incubated cells were normalized by dividing them through the average FR value of all control cells of the respective experimental cycle resulting in FR n .
In order to test the effect of acute application of statins, cells were incubated with Fura-2-AM as described above 1-2 days after seeding. Cells were superfused with control solution for 1 min in the experimental setup. Subsequently, histamine was applied up to three times at concentrations of 1-50 µM followed by a washout with control solution for 1-2 min. Statins were applied in concentrations of 50 and 100 µM to resting cells as well as during stimulation with 10 µM histamine.
All experiments were performed at room temperature between 20 and 23°C. Means ± SEM (n = number of cells) were calculated from pooled FR n . Statistical significance was tested by means of the two-sided Student's t-test.
Results
The long-term effect of statins on the resting intracellular calcium concentration was measured by preincubation of HUVEC cells for 24 h with the respective statins. Since the resting [Ca 2+ ] i levels varied from batch to batch, we expressed the statin effects as FR n , i.e. always normalized the fluorescence ratio to the values obtained from nontreated control cells. For 10 µM cerivastatin the FR n value was 1.104 ± 0.0103 (n = 72, P < 0.01). This means that statin incubation increased FR, which is a direct measure for an increase of the intracellular free calcium concentration, by 10.4%. 5 µM cerivastatin also increased FR n to 1.104 ± 0.0237 (n = 17) and 1 µM cerivastatin to 1.08 ± 0.0113 (n = 29). For 0.1 µM cerivastatin FR n was 1.01 ± 0.0122 (n = 30) which was not significantly increased (P = 0.29). Incubation with 10 µM fluvastatin increased FR n to 1.117 ± 0.0263 (n = 25, P < 0.01).
Thus, as summarized in Fig. 1, cerivastatin [17] . To check whether the increase of [Ca 2+ ] i after incubation with statins was caused by an increase of NO due to a direct activation of eNOS by statins, we tested the effect of cerivastatin in the presence of L-NAME, an inhibitor of eNOS. L-NAME alone had no effect on FR n . As shown in Fig. 1, 10 µM Cerivastatin increased FR n also in the presence of 50 µM L-NAME. Thus, we conclude that the observed effect of the statins on the resting calcium concentration is not a phenomenon common to all cells. In addition, it is not mediated by an direct (Ca 2+ -independent) effect of the statins on NO.
After 24 h incubation with one of the statins (or control group without statin) cells were stimulated with 10 µM histamine. Almost all cells have shown a typical increase of [Ca 2+ ] i (like those shown in Fig. 2 ). There was no obvious difference in the stimulated calcium transient pattern between the statin group and control group. Because of the large intercellular variability of the quantitative calcium response it was impossible to apply statistics for comparison between groups.
We further examined the effect of acute statin application to HUVEC cells on the resting [Ca 2+ ] i level as well as on histamine-induced Ca 2+ release. Cerivastatin or fluvastatin at concentrations between 50 and 100 µM were directly applied to the cells. In the absence of agonist, application of the statins for 1 to 5 min did not result in an effect on resting levels of [Ca 2+ ] i . In Fig. 2A such control applications are shown for fluvastatin.
The putative influence of statins on agonist-induced transients of [Ca 2+ ] i was tested with various protocols. As a control, a first Ca 2+ transient was elicited with histamine only. The subsequent Ca 2+ transient, again elicited with histamine, was then measured during simultaneous (Fig.  2B ) or preceded statin application (Fig. 2C) . In another series of experiments, statins were applied after the initial increase of [Ca 2+ ] i responding to the application of histamine, in order to test whether statins might primarily affect the return of [Ca 2+ ] i to basal levels. In none of these experiments histamine-induced Ca 2+ signals in HUVEC cells were significantly altered by statins.
Discussion
There is ample of evidence for so-called pleiotropic effects of statins -beneficial and vasoprotective effects which are independent on the lipid-lowering properties of these substances. Various authors have shown that statins are capable of modulating the flow properties of blood vessels. In vivo studies have shown after a short period of statin administration to humans a significantly increased blood flow under resting conditions and after stimulation [14] .
The underlying mechanism for this phenomenon is not completely understood. The results of Alvarez de Sotomayor et al. suggest that the improved vasodilatation is mainly mediated by an endothelium dependent relaxation which is induced by an increased production of nitric oxide [1] . An up-regulation of eNOS apparently plays an important role for this process [3, 10] . However, not only an up-regulation of eNOS expression may be responsible for a statin-induced increase of blood flow. Also the direct activation of eNOS is likely to contribute to endothelium dependent relaxation [19] .
Beside the activation of eNOS by mechanic stress, the calcium-calmodulin dependent activation of the enzyme in association with receptor-dependent and -independent agonists is the main pathway for the activation of eNOS; in contrast to iNOS, the activity of eNOS tightly correlates with [Ca 2+ ] i [4, 5] .
The concentration of free Ca 2+ in the cytosol is extremly low, whereas the concentration in the extracelluar space and in the endoplasmatic reticulum is high. When a signaling molecule like Histamin binds to a G-protein-linked receptor, phospholipase C-β becames activated. This enzyme generates two products: inositol triphosphate (IP3) and diacylglycerol. IP3 binds to IP3-gated Ca 2+ -release channels in the ER membrane. Ca 2+ rushes into the cytosol, dramatically increasing the local Ca 2+ concentration and triggering Ca 2+ -responsive proteins in the cells like eNOS: Ca 2+ binds to Calmodulin, a specific Ca 2+
Effect of 24-h statin incubation on the resting free calcium concentration , but it has no encyme activity itself. It acts by binding to other proteins and therby altering their activity. In this way it activates eNOS. It is well documented that IP 3 -mediated Ca 2+ release is also controlled by cytoplasmatic Ca 2+ concentration [11] . Small increases in calcium concentration around 100-300 nm enhance the activity of the IP3 receptor dramatically.
With One possible pathway leading to the increase in [Ca2+]i after incubation with statins could be via an increase of NO by means of direct eNOS activation by statins [17] . To exclude this hypothesis we compared cells incubated with 10 µM cerivastatin alone and cells incubated with 10 µM cerivastatin and 50 µM L-NAME as an inhibitor for the eNOS. In contrast to other L-Arginine inhibitors like L-NMMA, L-NAME has a different selectivity to the three NOS isoforms. The selectivity iNOS / eNOS is reported with 0,05 and the pIC50 with 5,82 for human isoencymes [2] . So, L-NAME is not highly active for eNOS inhibition, but for the applied concentration of 50 µM in HUVEC we expected a satisfied and selective inhibition of eNOS. [12] . The relationship between the integrated [Ca 2+ ] i and NO production was described by a straight line. This encourages us in the assumption that the observed changes of [Ca 2+ ] i through statins could be one possible mechanism for the improvement of endothelial function after treatment with these substances in vessels challenged by arteriosclerosis.
